Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775479 | 1.00 | CYP2D6 (0.49) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL3187502 | 0.81 | CYP2D6 (0.49) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL13483618 | 0.81 | CYP2D6 (0.49) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL769832 | 0.79 | CYP2D6 (0.46) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL9596277 | 0.78 | CYP2D6 (0.61) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL48088 | 0.78 | CYP2D6 (0.61) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL2916607 | 0.78 | CYP2D6 (0.61) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4187954 | 0.78 | CYP2D6 (0.45) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4182073 | 0.78 | CYP2D6 (0.45) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL8775418 | 0.76 | CHRM2 (0.46) | CYP2D6OPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532657-B9 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-04-19 | — | — | EP | disclosed |
| EP-2532657-B1 | Compounds and methods of use | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-08-31 | — | — | EP | disclosed |
| EP-2408300-B1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-8426585-B2 | Compounds comprising a spiro-ring | Xi, Ning (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2012-12-13 | — | — | US | disclosed |
| EP-2532657-A2 | Compounds and methods of use | Sunshine Lake Pharma Co., Ltd (CN) | 2012-12-12 | — | — | EP | disclosed |
| US-8293897-B2 | Compounds comprising a spiro-ring and methods of use | Xi, Ning (US) | 2012-10-23 | — | — | US | disclosed |
| US-8232294-B2 | Amino ester derivatives, sailts thereof and methods of use | Xi, Ning (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2408300-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd (CN) | 2012-01-25 | — | — | EP | disclosed |
| EP-2340244-A1 | COMPOUNDS AND METHODS OF USE | Xi, Ning (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010111063-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | XI NING (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| WO-2010045095-A1 | COMPOUNDS AND METHODS OF USE | XI NING (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-04-15 | — | — | US | disclosed |
| EP-0529688-B1 | Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes | DAIICHI SEIYAKU CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5508428-A | Spiro compound | DAIICHI PHAMACEUTICAL CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5286723-A | Spiro compound | DAIICHI SEIYAKU CO., LTD. | 1994-02-15 | — | — | US | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0529688-A2 | Azaspiro n,m alkanes and diazaspiro n,m -alkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0357047-A1 | Spiro compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SRC, BCAT1, BCAT2 | CYP2D6 4578/4885OPRL1 3092/4885OPRM1 4761/4885 |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | PRKDC, PRKACA, PRKX | CYP2D6 4784/4885OPRL1 4229/4885OPRM1 4639/4885 |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | CDC42BPG, HRAS, PTPRJ | CYP2D6 4177/4885OPRL1 4098/4885OPRM1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.